

# Amyloidosis (Amyloid light-chain (AL)) (short version)

Recommendations from the society for diagnosis and therapy of haematological and oncological diseases

## **Publisher**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
D-10117 Berlin

Executive chairman: Prof. Dr. med. Hermann Einsele

Phone: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Contact person**

Prof. Dr. med. Bernhard Wörmann  
Medical superintendent

## **Source**

[www.onkopedia-guidelines.info](http://www.onkopedia-guidelines.info)

The information of the DGHO Onkopedia Web Site is not intended or implied to be a substitute for professional medical advice or medical care. The advice of a medical professional should always be sought prior to commencing any form of medical treatment. To this end, all component information contained within the web site is done so for solely educational purposes. DGHO Deutsche Gesellschaft für Hämatologie und Onkologie and all of its staff, agents and members disclaim any and all warranties and representations with regards to the information contained on the DGHO Web Site. This includes any implied warranties and conditions that may be derived from the aforementioned web site information.

# Table of contents

<b>1 Summary .....</b>	<b>2</b>
<b>2 Therapy .....</b>	<b>2</b>
<b>15 Authors' Affiliations.....</b>	<b>4</b>
<b>16 Disclosures .....</b>	<b>4</b>

# Amyloidosis (Amyloid light-chain (AL)) (short version)

**ICD-10:** E85.-

**Date of document:** November 2022

## Compliance rules:

- [Guideline](#)
- [Conflict of interests](#)

**Authors:** Ute Hegenbart, Hermine Agis, Timon Hansen, Axel Nogai, Rahel Schwotzer, Stefan Schönland

## 1 Summary


Amyloidoses are rare protein folding diseases in which proteins are deposited as insoluble fibrillar aggregates as a result of a conformational change. This can be systemic (site of production and deposition different) or localized (site of production and deposition identical). Nomenclature is based on the amyloidogenic protein, which has superseded the previous classification into primary and secondary amyloidosis. Systemic amyloidoses are potentially life-threatening complications of monoclonal gammopathies (light chains, AL amyloidoses), age-related diseases (transthyretin, nonmutated; ATTRwt), chronic inflammation (serum amyloid A, AA amyloidoses), or they run in families as part of a monogenetic disease (most commonly transthyretin, TTR amyloidoses). The causal treatment of AL amyloidosis is the reduction of amyloid-forming light chains by immunochemotherapy. Early diagnosis of the disease is essential. At this stage, patients qualify for immuno-chemotherapy and can therefore still be treated effectively, thus avoiding further functional deterioration of the organs.

Patients should be presented to an amyloidosis center before initiating therapy, if possible. A list of centers can be found on the homepage of the German Society for Amyloid Diseases (<http://www.amyloid.de/>). There are also centers in Switzerland and Austria (Swiss Amyloidosis Network of the University Hospital Zurich <https://www.usz.ch/krankheit/amyloidose/>; Interdisciplinary Amyloidosis Center of the Medical University of Vienna).

## 2 Therapy

The current treatment algorithm is depicted in [Figure 1](#) and [Figure 2](#).

**Figure 1: First-line therapy for light chain (AL) amyloidosis**




**Legend:**

— non-curative treatment intent;

For composition and dosages of therapy regimens, see Appendix Therapy Protocols. PNP: polyneuropathy; Dara: daratumumab; Cy: cyclophosphamide; D: Dexamethasone; Boron or V: bortezomib; M or MEL: melphalan.

The risk classification is presented from [chapter 6.1.1.1](#) onwards (link to German version).

**Figure 2: Therapeutic options for relapsed/refractory light chain (AL) amyloidosis**



**Legend:**

— non-curative treatment intent;

For composition and dosages of the therapy regimens, see Appendix Therapy Protocols. Dara: daratumumab; Cy: cyclophosphamide; Dex: dexamethasone; V: bortezomib; Beda: bendamustine; Mel: melphalan; Len: Lenalidomide; Pom: Pomalidomide

## 15 Authors' Affiliations

### **Prof. Dr. med. Ute Hegenbart**

Universitätsklinikum Heidelberg  
Medizinische Klinik V  
Abt. Hämatologie/Onkologie  
Im Neuenheimer Feld 410  
69120 Heidelberg  
[ute.hegenbart@med.uni-heidelberg.de](mailto:ute.hegenbart@med.uni-heidelberg.de)

### **PD Dr. Hermine Agis**

Medizinische Universität Wien  
Klinik f. Innere Medizin I  
Abteilung Onkologie  
Währinger Gürtel 18-20  
AT-1090 Wien  
[hermine.agis@meduniwien.ac.at](mailto:hermine.agis@meduniwien.ac.at)

### **Dr. med. Timon Hansen**

Onkologikum Hämatologisch-Onkologische Praxis  
Altona (HOPA) MVZ GmbH  
Mörkenstr. 47  
22767 Hamburg  
[timon.hansen@hopa.de](mailto:timon.hansen@hopa.de)

### **Dr. Axel Nogai**

Charité - Universitätsmedizin Berlin  
(Campus Benjamin Franklin)  
Abt. Hämatologie, Onkologie, Tumormimmunologie  
Hindenburgdamm 30  
12203 Berlin  
[axel.nogai@charite.de](mailto:axel.nogai@charite.de)

### **Dr. med. Rahel Schwotzer**

Universitätsspital Zürich  
Klinik für Medizinische Onkologie und Hämatologie  
Rämistr. 100  
CH-8091 Zürich  
[rahel.schwotzer@usz.ch](mailto:rahel.schwotzer@usz.ch)

### **Prof. Dr. med. Stefan Schönland**

Universitätsklinikum Heidelberg  
Medizinische Klinik V  
Abt. Hämatologie/Onkologie  
Im Neuenheimer Feld 410  
69120 Heidelberg  
[stefan.schoenland@med.uni-heidelberg.de](mailto:stefan.schoenland@med.uni-heidelberg.de)

## 16 Disclosures

Conflicts of interest can be found in the [full German version of the guideline](#).